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Abstract
Background:  Neurofibromas are benign tumors of the peripheral nerves and hallmark of
neurofibromatosis type 1 (NF1), a tumor suppressor gene syndrome. Neurofibromas mostly start
developing at puberty and can increase in size and number during pregnancy. Expression of
progesterone receptors has been found in 75% of the tumors. Many female NF1 patients are thus
concerned about the possibility that hormonal contraceptives may stimulate the growth of their
neurofibromas.
Methods: A survey was carried out on 59 female NF1 patients who are practicing or have
practiced hormonal contraception to examine the effect of the various contraceptives on the
growth of neurofibromas.
Results: Majority (53 out of 58) of patients who received oral estrogen-progestogen or pure
progestogen preparations reported no associated tumor growth. In contrast, significant tumor
growth was reported by two patients who received depot contraceptive containing high dose of
synthetic progesterone.
Conclusions: Oral contraceptives do not seem to stimulate the growth of neurofibromas in NF1
patients. High doses of progesterone might stimulate the growth of neurofibromas and deserve
more caution.
Background
Neurofibromatosis type 1 (NF1) is a genetic disorder with
an incidence of about 1 in 3000. Multiple neurofibromas
are the most significant hallmark of NF1. These benign
tumors of peripheral nerves mostly start developing at
puberty and can increase in size and number during preg-
nancy [1]. Since decades, physicians involved in the care
of NF1 patients are concerned by the dilemma if hormo-
nal contraceptives containing estrogen and progestogen
could stimulate the onset of new or the growth of the yet
present neurofibromas. Recently, McLaughlin & Jacks [2]
reported expression of progesterone receptors and estro-
gen receptors in 75% and 5% of 59 neurofibromas immu-
nohistochemically, respectively. The authors thus inferred
an important role of progesterone in neurofibroma
growth and suggested that antiprogestins may be useful in
the treatment of this tumor.
Hormonal contraceptives contain synthetic progestogen
which bind to the progesterone receptors. Depending on
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the formulation of the currently available preparation,
combined oral contraceptives contain 0.02 to 0.05 mg
synthetic estrogen and low doses of various types of syn-
thetic progestogen. These kinds of contraceptives suppress
the pituitary gonadotropin secretion and thus reduce the
endogenous levels of estrogen and progesterone. The defi-
ciency of endogenous estradiol is balanced by the exoge-
nous supply of ethinylestradiol. Synthetic progestogen
bind to progesterone receptors and thus compensate the
deficiency of endogenous progesterone to certain extent.
Progestogen-only preparations, such as the so-called pro-
gestogen-baby-pills, contain progestogen that is below the
ovulation-inhibiting dose. This kind of pills only suppress
the peak levels of the gonadotropins and thus reduce the
estrogen and progesterone level to certain degree. In con-
trast, parenteral progestogen preparations (depot contra-
ceptives) contain high doses of medroxyprogesterone
acetate (150 mg) or norethisteron enanthat (200 mg). In
the first days after the administration of these prepara-
tions, the blood concentration of progestogen is very high
which decreases slowly over weeks.
To examine the effect of hormonal contraceptives on the
behaviour of neurofibromas, we carried out a survey on
59 female NF1 patients in this study.
Methods
NF1 was diagnosed according to the NIH criteria [3]. The
protocol was approved by the institutional review board
and all participants provided informed consent. A total of
110 female NF1 patients of the NF-Clinic Hamburg, Ger-
many, were asked to fill out a question form (appendix in
additional file 1) and some of them were interviewed per-
sonally by the authors. Only patients who have or had
neurofibromas were included in this survey. The age of the
included patients was between 18 and 80 years. Data col-
lection was done from Aug. to Dec. 2003, except for one
patient who changed preparation in Dec. 2003 and pro-
vided us new information recently. The major informa-
tion acquired were: age of menarche, paramenia,
contraceptive means and behaviour of their neurofibro-
mas (appendix in additional file 1). Patients were asked to
describe the increase of the growth of their neurofibromas
as either slight, medium, significant or no (appendix in
additional file 1).
Results
Among the total of 110 patients included in the survey, 69
were practicing or had practiced hormonal contraception.
Sixty-three received oral estrogen-progestogen prepara-
tions, 3 had pure progestogen and one had been given a
parenteral depot contraceptive containing very high dose
of medroxyprogesterone acetate (150 mg) and norethis-
terone enanthate (200 mg). For two patients, the names of
the preparations could no longer be recalled. Eight out of
the 63 patients who used oral estrogen-progestogen could
not recall whether there was any change in the behaviour
of their neurofibromas in association with hormonal con-
traception and were excluded from further evaluation.
Data from a total of 59 patients were thus available for
evaluation (table 1). The period of hormonal contracep-
tion was between 3 months and 22 years among these 59
patients. Fifty three (91%) out of the 58 patients who used
combined estrogen-progestogen preparation or pure pro-
gestogens were convinced that there was no tumor growth
in association with the practiced hormonal contraception.
Other five patients reported a slight increase in the size or/
and number of their neurofibromas in the first few
months of the hormonal contraception. These 5 patients
used combined estrogen-progestogen preparation, con-
taining 0.03 to 0.05 mg of estrogen and 0.125 to 2.5 mg
synthetic progestogen (table 2). However, no tumor
growth was reported by other 15 patients who also used
the same preparation (table 2).
One patient received a depot progestogen (Depot-Clino-
vir) and reported a strong growth of neurofibromas and
intraspinal tumors right after begin of the hormonal con-
traception. In December 2003, after the closure of our
data collection, one patient changed from a combined
contraceptive to the depot contraceptive Depot-Clinovir.
Recently, she reported experience of rapid growth of her
neurofibromas since the change. Interestingly, her tumors
had been stable during the two years she took combined
contraceptive (Ministon, Leios).
Table 1: A survey on 59 female NF1 patients practicing hormonal contraception
No alteration in tumors 
behavior
Slightly increase in tumor 
size or/ and number
Significant tumor growth Total
Estrogen/progestogen, oral 50a 55 5 a
Pure progestogen, oral 3 0 3
Pure progestogen, depot 2a 2a
aOne patient had received oral estrogen/progestogen until Dec. 2003, and then changed to depot pure progestogen.BMC Cancer 2005, 5:16 http://www.biomedcentral.com/1471-2407/5/16
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Of the 7 patients whose neurofibromas had increased in
size and number upon hormonal contraception, two had
been treated for paramenia as adolescents, while the other
4 were gynecologically normal.
Discussion
Our results suggest that in majority of cases, combined
hormonal contraceptives containing estogen and pro-
gestogen do not seem to stimulate growth of neurofibro-
mas in NF1 patients. The reported slight tumor growth in
5 cases may not necessarily be the consequence of the con-
traceptives since other patients who used the same prepa-
ration did not notice related tumor growth (table 2). Our
finding seems to eliminate the previous uncertainty and
excessive caution in using hormonal contraceptives which
often mean exporing NF1 patients to more severe prob-
lems as undesired pregnancies with important effects on
tumoral growth.
The significant tumor growth associated with depot con-
traceptive in two cases suggests that high doses of medrox-
yprogesterone acetate and nerethisterone enanthate might
stimulate the growth of neurofibromas in some cases.
However, only two cases are far too few for further specu-
lation. Additional reports and reviews regarding response
of NF1 patients to this form of contraception will be very
helpful.
Our survey was done a posteriori and mostly by a question-
naire. The results thus report only subjective impressions
of patients, not an objective and quantifiable judgment of
the researcher. This is clearly a major limitation of the
study. Use of cultured Schwann cells and fibroblasts from
human neurofibromas as well as recently developed
mouse models of neurofibromas may help to further dis-
sect the role of progesterone in regulating neurofibroma
growth.
Conclusions
Oral contraceptives do not seem to stimulate the growth
of neurofibromas in most cases and thus may be used by
NF1 patients. High doses of progesterone might stimulate
the growth of neurofibromas and deserve closer
observation.
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Additional material
Table 2: Contraceptives reported to be associated with tumor growth
Contraceptive 
(Commercial name)
Type Composition Number of patients who 
experienced tumor growth
Number of patients who 
did not experience tumor 
growth
Non-Ovlon combined oral 0.05 mg estrogen
1.0 mg noreethisteron acetate
1
slight
7
Marvelon combined oral 0.03 mg estrogen
0.15 mg desogestrel
1
slight
6
Femranette combined oral 0.03 mg estrogen
0.15 mg levonorgestrel
1
slight
1
Trisiston combined oral 0.03 mg estrogen
0.125 mg levonorgestrel
1
slight
1
Ovanon combined oral 0.05 mg estrogen
2.5 mg lynestrenol
1
slight
1
Depot-Clinovir parenteral progestogen 150 mg medroxyprogesterone acetat
200 mg norethisteron enanthat
2
significant
0
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